Akebia Therapeutics, Inc. (AKBA) EPS Estimated At $-0.51

July 14, 2018 - By Jimmy Baldridge

Akebia Therapeutics, Inc. (NASDAQ:AKBA) LogoInvestors sentiment increased to 1.9 in 2018 Q1. Its up 0.27, from 1.63 in 2017Q4. It increased, as 14 investors sold Akebia Therapeutics, Inc. shares while 28 reduced holdings. 37 funds opened positions while 43 raised stakes. 39.14 million shares or 29.30% more from 30.27 million shares in 2017Q4 were reported.
Citigroup Inc reported 35,859 shares stake. Ameritas Inv Ptnrs stated it has 3,813 shares. Johnson Invest Counsel Incorporated has 0.01% invested in Akebia Therapeutics, Inc. (NASDAQ:AKBA) for 61,567 shares. Raymond James And holds 0% of its portfolio in Akebia Therapeutics, Inc. (NASDAQ:AKBA) for 38,761 shares. Goldman Sachs Grp reported 781,457 shares or 0% of all its holdings. Prelude Capital Mngmt Ltd Company invested in 12,383 shares. D E Shaw invested in 0% or 31,714 shares. Dekabank Deutsche Girozentrale holds 0% or 20,600 shares. Tiaa Cref Investment Ltd owns 0% invested in Akebia Therapeutics, Inc. (NASDAQ:AKBA) for 220,269 shares. New York-based Jane Street Gp Ltd Liability has invested 0% in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Alliancebernstein L P owns 0% invested in Akebia Therapeutics, Inc. (NASDAQ:AKBA) for 43,200 shares. Opus Point Prtn Mngmt Limited Liability reported 0.94% stake. Secor Capital Ltd Partnership accumulated 69,749 shares or 0.05% of the stock. State Of Wisconsin Invest Board holds 26,000 shares. Verition Fund Ltd Liability Corporation invested in 13,739 shares or 0.01% of the stock.

Since February 15, 2018, it had 0 buys, and 1 insider sale for $14,620 activity.

Analysts expect Akebia Therapeutics, Inc. (NASDAQ:AKBA) to report $-0.51 EPS on August, 14.They anticipate $0.02 EPS change or 3.77 % from last quarter’s $-0.53 EPS. After having $-0.48 EPS previously, Akebia Therapeutics, Inc.’s analysts see 6.25 % EPS growth. The stock decreased 1.00% or $0.1 during the last trading session, reaching $9.95. About 491,115 shares traded. Akebia Therapeutics, Inc. (NASDAQ:AKBA) has declined 25.63% since July 14, 2017 and is downtrending. It has underperformed by 38.20% the S&P500.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor biology. The company has market cap of $566.29 million. The Company’s lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. It currently has negative earnings. The firm is also developing a HIF portfolio of product candidates that include AKB-6899 for the treatment of anemia; and AKB-5169, a preclinical compound for the treatment for inflammatory bowel disease.

More news for Akebia Therapeutics, Inc. (NASDAQ:AKBA) were recently published by: Seekingalpha.com, which released: “Keryx Biopharmaceuticals And Akebia Therapeutics: Was The Reaction To The Merger Announcement Justified?” on July 06, 2018. Seekingalpha.com‘s article titled: “Akebia Therapeutics, Keryx Biopharma agree to merge” and published on June 28, 2018 is yet another important article.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.